Tirabrutinib (ONO-4059) 是一种口服有效的高选择性Bruton’s Tyrosine Kinase(BTK) 抑制剂 (能透过血脑屏障),其IC50值为 6.8 nM。Tirabrutinib 不可逆共价结合BTK并抑制异常 B 细胞受体信号传导。Tirabrutinib 可用于自身免疫性疾病和血液学恶性肿瘤的研究。
生物活性 | Tirabrutinib (ONO-4059) is an orally activeBruton’s Tyrosine Kinase(BTK) inhibitor (can cross the blood-brain barrier (BBB)), with anIC50of 6.8 nM. Tirabrutinib irreversibly and covalently binds toBTKand inhibits aberrant B cell receptor signaling. Tirabrutinib can be used in studies of autoimmune diseases and hematological malignancies[1][2][3][4]. |
体外研究 (In Vitro) | Tirabrutinib (0.1-1000 nM or 0.001-100 nM; 72 h) inhibits the proliferation of OCI-L Y10 and SU-DHL-6 cells with IC50s of 9.127 nM, and 17.10 nM, respectively[1]. Tirabrutinib (0.5, 5, 50 μM; 24, 48 h) induces SU-DHL-6 cells apoptosis needs high dosage and prolonged administration (concentration up to 50 μM and incubates for 48 h)[1]. Tirabrutinib (300 nM, 72 h) induces caspase-3 and PARP cleavage in TMD8 cells[2].
Cell Proliferation Assay[1] Cell Line: | SU-DHL-6 and OCI-L Y10 cells | Concentration: | 0.1-1000 nM; 0.001 nM-100 nM | Incubation Time: | 72 h | Result: | Showed good anti-proliferative activity with IC50s of 9.127 nM, and 17.10 nM for OCI-L Y10 and SU-DHL-6 cells, respectively. |
Apoptosis Analysis[1] Cell Line: | SU-DHL-6 cells | Concentration: | 0.5, 5, 50 μM | Incubation Time: | 24, 48 h | Result: | Induced cell apoptosis when concentration up to 50 μM and incubated for 48 h. |
Western Blot Analysis[2] Cell Line: | TMD8 cells | Concentration: | 300 nM | Incubation Time: | 72 h | Result: | Induced caspase-3 and PARP cleavage. |
|
体内研究 (In Vivo) | Tirabrutinib (10 mg/kg; p.o.; single) is rapidly absorbed into plasma and brain, and reaches Cmax(blood Cmax=339.53 ng/mL; brain Cmax=28.9 ng/mL) 2 hours post administration[1]. Tirabrutinib (6, 20 mg/kg; p.o.; single daily for 3 weeks) shows inhibition of tumour growth in vivo[2].
Animal Model: | Male SD rats (219.0–260.5g)[1]. | Dosage: | 10 mg/kg | Administration: | Oral administration; single. | Result: | 1.19Pharmacokinetic Parameters of Tirabrutinib in male SD rats[1].
| Plasma, Cmax(ng/mL) | Brain, Cmax(ng/mL) | Penetration rate (%, Cmax, brain/Cmax, plasma) | PO (10 mg/kg) | 339.53 | 28.9 | 8.5 |
|
Animal Model: | Immunodeficiency (SCID) mice (mouse xenograft model)[2]. | Dosage: | 6, 20 mg/kg | Administration: | Oral administration; single daily for 3 weeks. | Result: | Inhibited tumour growth, and when dosage up to 20 mg/kg, a complete tumor suppression at day 14. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(220.03 mM) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 2.2003 mL | 11.0016 mL | 22.0032 mL | 5 mM | 0.4401 mL | 2.2003 mL | 4.4006 mL | 10 mM | 0.2200 mL | 1.1002 mL | 2.2003 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.50 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.50 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.50 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|